Clinical Burden and Costs of Anti-Neutrophil Cytoplasmic Antibody-ANCA-Associated Vasculitis: Main Findings from REDCap Registry of a University Hospital in Spain

Abstract

Juliana Draibe,1 Laura Martinez Valenzuela,1 Francisco Gomez-Preciado,1 Paula Anton-Pampols,1 Ana Melissa Rau,1 Helena Díaz-Cuervo,2 Carlos Crespo,2,3 Jesús Cuervo,2 Antonio Ramirez de Arellano4 1Nephrology Department, Hospital Universitari de Bellvitge, Barcelona, Spain; 2Axentiva Solutions, Barcelona, Spain; 3Department of Statistics, University of Barcelona, Barcelona, Spain; 4CSL Vifor, Zürich, SwitzerlandCorrespondence: Juliana Draibe, Nephrology Department, Hospital Universitari de Bellvitge, Feixa Llarga, s/n, Barcelona, Catalonia, Spain, Email [email protected]: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are rare chronic autoimmune diseases, potentially fatal, with frequent relapses. They are associated with vital organ damage, especially renal, often resulting in end-stage renal disease. While current standard of care with immunosuppressants has improved renal function and survival, the main risks for patients under life-long immunosuppression are infections and other concomitant diseases. This study evaluated the burden of AAV using patient-level data from a disease-specific registry.Patients and Methods: The cohort of incident AVV patients (2013– 2022) in the REDCap registry in a university hospital in Spain was studied. Patients with Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA) with at least one year of follow-up (or deceased during the period) were included. Clinical outcomes, including Birmingham Vasculitis Activity Score (BVAS) and healthcare resource consumption were analysed for the first year after diagnosis. Mean annual costs were calculated using unitary costs from the hospital accounting department.Results: Seventy-five patients (12% EGPA, 32% GPA, and 56% MPA) were included. Fifty-two percent were women. Mean age at diagnosis was 65.20± 14.70 years. At baseline, mean BVAS was 17.35± 5.70, 93.33% of patients showed renal affectation, mean estimated glomerular filtration rate was 33.32± 29.93mL/min/1.73m2. As induction treatment, 62.67% received methylprednisolone, 37.33% rituximab, 25.33% cyclophosphamide, 14.67% rituximab plus cyclophosphamide, 34.67% plasmapheresis. During the first year after diagnosis, 17.33% relapsed and 78.67% had at least 1 hospitalisation; 97.33% received steroids; 13.33% were on dialysis at some point; one patient received a kidney transplant; 46.67% presented infections and 28% suffered corticosteroid-associated complications; 4 patients died, being 50% of deaths treatment-related. The highest observed mean cost per patient for the first year was € 11,647.95 for hospital care.Conclusion: This study revealed a considerable burden of AAV, as evidenced by high rates of hospitalisation, relapses, and the need for intensive medical interventions.Keywords: anti-neutrophil cytoplasmic antibody-associated vasculitis, vasculitis, disease burden, registry, treatment outcome

Keywords

• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
• Vasculitis
• Disease burden
• Registry
• Treatment outcome.